The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.
“The depth of our research at ACC this year is a testament to how our medicines help improve care for people living with cardiovascular diseases, type 2 diabetes and diabetic kidney disease,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. “We look forward to sharing the latest evidence from our portfolio that we believe will continue to help shape clinical practice.”
Janssen’s cardiovascular and metabolism franchise includes XARELTO®, a direct oral anticoagulant (DOAC) with eight indications – the most of any DOAC in the class – and INVOKANA® (canagliflozin), the only type 2 diabetes (T2D) medicine proven to slow the progression of diabetic nephropathy, also known as diabetic kidney disease (DKD), and reduce the risk of hospitalization for heart failure in patients with T2D and DKD with albuminuria >300 mg/day.
Highlights from the Janssen cardiovascular and metabolism portfolio to be presented during ACC.20/WCC include:
- VOYAGER PAD (main results and subgroup analysis): The first Phase 3 randomized study to evaluate a dual pathway approach with XARELTO® (2.5 mg twice daily) plus aspirin (100 mg once daily) for reducing the risk of major adverse limb and cardiovascular (CV) events in patients with symptomatic PAD undergoing lower-extremity revascularization (a procedure to improve blood flow in the legs). A prespecified subgroup analysis that evaluated outcomes in patients who received clopidogrel will also be presented.
- COMPASS (diabetes analysis): A prespecified subgroup analysis from the COMPASS study evaluated the benefit of XARELTO® (2.5 mg twice daily) plus aspirin (100 mg once daily) in patients with stable coronary artery disease (CAD) and/or PAD with T2D versus those without T2D. Primary results from COMPASS showed that the dual pathway approach of XARELTO® plus aspirin significantly reduced the risk of major CV events in patients with chronic PAD and/or CAD compared to aspirin alone.
- PRONOMOS: This randomized study evaluated the use of XARELTO® in preventing venous thromboembolism (VTE), or blood clots, in patients after undergoing non-major orthopedic surgery.
- CREDENCE: Four new analyses from the CREDENCE study in T2D and DKD examined the effect of INVOKANA® on specific patient subgroups. Primary endpoint results from CREDENCE showed INVOKANA® significantly reduced the composite risk of end-stage kidney disease (ESKD), doubling of serum creatinine and renal or CV death in patients with DKD and T2D, and also reduced the risk of hospitalization for heart failure.